PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2023/33 - LusoPalex / Isoder
Acquired
Isotopos e Derivados (ISODER), S.A.
Description
Company currently owned by a group of individual and business shareholders, which operates, exclusively in Portugal, in the distribution of medicines for human use in the field of nuclear medicine and medical devices for in vitro diagnosis.
Acquiring
Lusopalex - Produtos de Saúde Unipessoal, Lda.
Description
Portuguese company currently owned by Palex Medical, S.A.U., whose activity is the import, export, distribution and sale of hospital and laboratory equipment, surgical prostheses, hospital clinical material, research and in vitro diagnostic reagents, microscopy equipment and solutions technologies aimed at research, diagnosis and the food industry, equipment and consumables for cardiology.
Sector
  • Trade and Services
Activity (NACE)
  • G4646 - Wholesale of pharmaceutical goods
Applicable legislation
Art. 37(1)(a) (Law 19)
Notification thresholds
Market Share threshold
Type of merger
Horizontal
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description

The merger in question consists of the acquisition, by LusoPalex – Produtos de Saúde Unipessoal, Lda. (“LusoPalex”), of the exclusive control of the company Isótopos e Derivados (Isoder), S.A. and, indirectly, of its subsidiary Fardiotop, Produtos e Serviços Farmacêuticos, Lda. (“Fardiotop”).
Timeline
2023-09-06
The AdC issued a non-opposition decision to the merger LusoPalex / Isoder.
2023-08-18
LusoPalex notifies the acquisition of exclusive control over Isoder.
Click here to see your activities